Teleflex Incorporated
Teleflex Incorporated (TFX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
tfx · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Teleflex Incorporated (TFX) measures how much investors pay for each dollar of the company's trailing earnings. TFX's current PE ratio of N/A is calculated by dividing its stock price of $132.65 by its TTM earnings per share of -$22.79.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 18 fiscal years · Front-end computedMinQ1 · 25%27.5x
MedianQ3 · 75%119.6x
Max
At N/A, TFX's current P/E is lower than in 0% of its annual fiscal year readings over the past 18 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Instruments & Supplies · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Teleflex IncorporatedYou TFX | $5.9B | N/A | — | -$22.79 |
 Alkermes plc ALKS | $7.2B | 19.07x | -39.5% | $1.47 |
 Arrowhead Pharmaceuticals, Inc. ARWR | $10.4B | N/A | — | -$0.01 |
 Bausch + Lomb Corporation BLCO | $5.4B | N/A | — | -$1.02 |
 CRISPR Therapeutics AG CRSP | $5.0B | N/A | — | -$6.47 |
 Krystal Biotech, Inc. KRYS | $9.0B | 34.84x | +10.6% | $7.08 |
 Merit Medical Systems, Inc. MMSI | $3.9B | 40.58x | +28.8% | $2.17 |
Industry Average 3 peers with valid PE | — | 31.50x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-20.30 | — | |
2024-12-31 FY2024 | 119.64x | $1.49 | +263.9% | |
2023-12-31 FY2023 | 32.87x | $7.58 | +2.0% | |
2022-12-31 FY2022 | 32.24x | $7.74 | +1.8% | |
2021-12-31 FY2021 | 31.65x | $10.38 | -44.5% | |
2020-12-31 FY2020 | 57.06x | $7.21 | +51.4% | |
2019-12-31 FY2019 | 37.69x | $9.99 | -35.9% | |
2018-12-31 FY2018 | 58.81x | $4.39 | -19.9% | |
2017-12-31 FY2017 | 73.41x | $3.39 | +149.6% | |
2016-12-31 FY2016 | 29.41x | $5.48 | +31.8% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Teleflex Incorporated (TFX) measures how much investors pay for each dollar of the company's trailing earnings. TFX's current PE ratio of N/A is calculated by dividing its stock price of $132.65 by its TTM earnings per share of -$22.79.
Frequently asked questions
TFX pe ratio · 6 questionsTFX's current PE ratio is N/A as of 2026-06-08, based on a stock price of $132.65 and TTM EPS of -$22.79. Data sourced from Financial Modeling Prep via TFX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Teleflex Incorporated SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08